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ABSTRACT 
Non-antibiotics affect bacterial susceptibility towards antibiotics in a multifactorial manner, including perturbation of 
membrane energetic and a possibly direct interaction with drug efflux transporters themselves. Thus, efflux inhibiting 
compounds affect susceptibilities to antibiotics that act either intracellular or at the bacterial wall. Therefore they may 
be applied as helper compounds to conventional antibiotic treatments. A valid definition of the effect of these com-
pounds is crucial. Conventional microbiological quotations such as checkerboard or MIC definition do not discriminate 
the complexity of a system where several compounds interact with several targets both on the bacterial membrane and 
soma. We presume the fact, that certain resistance mechanisms, such as efflux, are neither adequately nor precisely 
monitored, utilizing the established microbiologic screening tools, such as agar- or microdilution techniques. In this 
context this paper may contribute as an innovative step, utilizing mathematic modeling in order to describe interactions 
on the surface of microorganisms. Thus, mathematical modeling might be a tool which can be adopted to optimize the 
description of certain forms of bacterial resistance, as well as the influence of antibacterial drugs on such targets which 
interact with bacterial outer-membrane transport mechanisms. This paper presents modeling of bacterial population 
dynamics as an attempt to precise complex compound target interaction. Furthermore, the importance of a synergetic 
coupling term in the model is exemplified by comparison with experimental data of Kumar et al. [1]. A specific proce-
dure for extraction of model coefficients is devised for further experimental studies of the coupling between an antibi-
otics and a helper compound. In particular, it is found that the scarce experimental data of Kumar et al. [1] can be fitted 
to the mathematical model demonstrating synergetic effects of non-antibiotics. 
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1. Introduction 
The development of resistance in microorganisms against 
usual clinical antimicrobial agents is increasing all over 
the world. New antibacterial molecules and new thera-
peutic approaches are needed to overcome the multi drug 
resistance (MDR) and the (XMDR) in severe infectious 
diseases [1-6]. 
In the laboratories new methods are needed to predict 
the different resistance mechanisms [7] active in the mi-
croorganisms and to overcome these [8-10]. The classical 
calculations to be used to estimate synergy/antagonism 
and indifference in combination treatment with classical 
antimicrobial agents are insufficient. The (experimentally) 
pronounced synergy called: REVERSAL OF RESIS-
TANCE between antibiotics and non antibiotics is not 
always to be found with the classical mathematical esti-
mation models in the clinical microbiology laboratory 
[11-13]. 
Reversal of resistance in different biological systems 
and in microorganisms by help of non antibiotics as 
“helper compounds”, has been pointed out over the last 
decade [10,14-16] as one clinical possibility to be util-
ized in order to reverse bacterial resistance in vivo [10]. 
Interestingly, one group of compounds which is not 
described as anti-infective agents is found to be strong 
candidates for development as “helper compounds”. These 
are the drugs used for non infectious diseases which can 
exhibit some antimicrobial activities. Especially the com- 
pounds having activity on the peripheral and central 
nerve system, in humans, seem to be promising. These 
naturally and synthetic compounds are used in the clini-
cal pharmacology as universal and local anesthetics and 
as psychopharmacological agents including their stereo- 
isomeric analogues [17]. The common actions of these 
drugs are their blocking effects on the transporters activ-
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ity located in different eukaryotic and prokaryotic cell 
membranes in vitro and in vivo. Furthermore, molecu-
lar/genetic principles have significantly contributed to 
our understanding of the regulation and function of re-
sistance mechanisms [7,18-25]. 
Anti-microbial agents are inactivated by the following 
resistance mechanisms [7]. 
 Inactivation or modification of the antibiotic. 
 Target modification or protection. 
 Reduced intracellular accumulation caused by reduced 
permeability and/or increased efflux. 
MDR efflux pumps and modification of membrane 
proteins involved in the antibiotic penetration are based 
on the regulation of transporters genes. Ongoing studies 
which focus on the activity of bacterial efflux influenced 
by phenothiazine’s, confirm the hypothesis, that modifi-
cation of resistance is related to the inhibition of efflux- 
pumps [14,18,26]. 
Utilizing these known old drugs as “helper com-
pounds” together with usual clinical antibiotics on MDR 
and XMDR pathogens in the combination antimicrobial 
therapy in patients with severe infectious diseases is a 
challenge. Extended mathematical modeling might be a 
possibility to predict the best combination of molecules 
to reach the desired reversal of resistance on the back-
ground of clinical microbiological investigations. Also 
many of the pharmacological kinetic questions to be an-
swered might be calculated in these mathematical models, 
especially when mathematic modeling is focusing on the 
above mentioned membrane target sites. The purpose of 
the present study is to answer a few of the above ques-
tions by developing a mathematical model on the back-
ground of different in vitro and in vivo microbiological 
investigations [1,27,28]. 
2. Modeling of Bacterial Population Dynamics 
A set of ordinary differential equations is formulated 
assuming three dynamic variables: Bacteria concentra-
tion N, helper compound concentration P1, and antibiotic 
concentration P2. Here we emphasize that the bacteria 
concentration N initially is assumed to be “naïve”, i.e., 
not previously exposed to antimicrobial agents. The set 
of equations is as follows: 
  
2
1 2 3 1 4 2
5 1 2
d d  N t ε N ε N ε P N ε P N
ε P P N a bN H N
   
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where N is the bacteria concentration with N(0) = 1 × 104 
CFU/ml, and 
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are the drug concentrations with Pi(0) = 0 μg/mL. The 
parameters εi; a; b; ki; fi are constants in the absence of 
dynamic immunization and H(N) is the Heaviside func-
tion. Si(t) is a source function for the injection of drug Pi. 
The model takes into account growth of bacteria in the 
absence of drugs (ε1—term), bacteria interaction phe-
nomena (bacteria food, respiration, and waste restrictions) 
that limit the upper concentration level of bacteria (ε2), 
coupling mechanisms between bacteria and helper com-
pound (ε3) as well as bacteria and antibiotics (ε4). For 
example the ε3 term in the first equation is proportional 
to the simultaneous concentration of the helper com-
pound P1 and the bacteria concentration N. If ε3 is posi-
tive (negative) the coupling term leads to a decrease (in-
crease) in bacteria concentration. An additional multi- 
coupling effect is introduced involving all three dynamic 
variables (ε5). This coupling reflects the synergy term 
between the helper compound (P1) and the antibiotics (P2) 
in decreasing the bacteria concentration. We also include 
the effect of the host immune defense system by adding a 
term—(a+bN)H(N) that keeps the bacteria concentration 
down for controlled infections. A more detailed formula-
tion of the immune defense action similar to that de-
scribed in [9] could easily be incorporated. The dynamics 
of the helper compound and antibiotics involve exponen-
tial concentration decay over time upon injection in the 
host (coefficients k1 and k2 corresponding to different 
decay rates). Drug injections are controlled externally by 
source terms fiSi(i = 1;2). 
A case study involving varying number of active coef-
ficients are carried out and discussed in the following. 
The general parameter values are listed in Table 1 and 
used in the case studies unless otherwise stated. 
Figure 1 shows the drug injection profiles as function 
of time Si(t) for the helper compound (blue curve) and 
the antibiotics (red curve). The terms are normalized so 
that the integral of Si(t) is unity. 
In Figure 2(a), we plot the resulting bacteria concen-
tration dynamics. The injection forcing amplitudes of 
helper compound and antibiotic is f1 = 0.5 and f2 = 1. 
Note the exponential increase and subsequent saturation 
of the bacteria concentration as expected. At the time for 
the helper compound injection we see the gain effect of 
 
Table 1. Basic parameters for the case studies. 
Parameter Value 
ε1 0.1 
ε2 0.1 
ε3 –0.003 
ε4 0.7 
ε5 0.9 
a 1 × 10–6 
b 1 × 10–7 
k1 0.01 
k2 0.05 
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Figure 1. Source functions for P1(t) (blue) and P2(t) (red), f1 
= f2 = 1. 
 
 
(a) 
 
(b) 
Figure 2. (a) Dynamics including coupling term resulting in 
complete kill. (b) with no coupling term (ε5 = 0) the model 
results in reactivation of the bacterial level. 
 
the helper compound on the bacteria population (since ε3 
In Figure 
is negative). 
2(a) it is seen that the immune system is 
st
3. Experimental Characterization of 
Th erification using experimental 
and 
an
iotics compound in the absence of bacteria 
an
bacteria population in the ab-
se
ng a certain amount of helper compound f1S1 
(b
tibiotics f2S2 (but 
rong enough to maintain the bacteria concentration at a 
low insignificant level in the case where the coupling 
term is activated. Basically, this case demonstrates a 
“successful” situation where the addition of antibiotics 
cures the patient. In the absence of a helper compound 
the bacterial level will increase again, hence the antibi-
otic itself is not sufficient. It is only due to the action of 
the coupling term (represented by ε5) that a successful 
kill is attained. The term involving ε5 is effective only if 
both the antibiotic and the helper compound concentra-
tions are nonzero simultaneously! This is demonstrated 
in Figure 2(b) where we simulate the system with the 
coupling term (ε5 = 0). In this case, a pure additive model 
is effected and model results confirm that in the absence 
of the drug coupling the bacteria population eventually 
recovers. This demonstrates the gain in coupling drugs so 
as to obtain a stronger killing of bacteria—even though 
the effect of the helper compound may be non-antibiotic. 
Administration times are chosen arbitrarily for the case 
study considered in Figure 2—it is just an example. In 
actual fact, our model can easily handle any other ad-
ministration choice. For the estimation of the mathe-
matical model parameters it is important to be able to 
administer the addition of helper compound and antibi-
otics differently as explained below. The set of experi-
mental studies suggested there is a minimum for the de-
termination of all parameters in an unambiguous way and 
therefore a complete mathematical study. 
Model Parameters 
e above model requires v
data. In particular, a set of experimental studies is sug-
gested to provide information about model parameters. 
This protocol of experiments may serve as inspiration to 
future works aiming to provide experimental basis for 
development and validation of mathematical models. 
Inject helper compound in the absence of bacteria 
tibiotics. The dynamic behavior of P1 allows k1 to be 
determined. 
Inject antib
d helper compound. The dynamic behavior of P2 al-
lows k2 to be determined. 
Study the evolution of 
nce of helper compound and antibiotics. At least four 
data points at distinct times allow ε1, ε2, a, and b to be 
specified. 
Now addi
ut not antibiotics!) to the bacteria population at a cer-
tain time and studying the evolution of the bacteria 
population allows ε3 to be determined. 
Now adding a certain amount of an
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no
 parameter ε5 is to 
fin
riments, the mathe-
m
t take into account changes 
in
4. Estimation of Model Coefficients—Case 
r 
In 
ree organs: Heart 
bl
ents the saturation term is not 
ex
t helper compound!) to the bacteria population at a 
certain time and studying the evolution of the bacteria 
population allows ε4 to be determined. 
A simple way to obtain the coupling
ally add both f1S1 and f2S2 with temporal overlap. 
Studying the influence of bacteria population allows the 
last parameter ε5 to be found. 
Given the above scenario of expe
atical model must be verified against independent ex-
perimental data involving the same bacteria type, antibi-
otics, and helper compound. 
The present model does no
 the decay rate of the helper compound due to biologi-
cal trapping or degradation by bacteria. In principle such 
effects can be built into the model but to simplify the 
analysis this is not done here. Our comparison with the 
experimental data of Kumar et al. [1] in the following 
section shows that the present model is able to capture 
the essential dynamics. However, due to the scarce data 
of Kumar et al. it is not possible to conclude further on 
these effects. 
Study on Mice with Amlodipine as Helpe
Compound and Streptomycin as Antibiotics 
the paper by Kumar et al. [1], a series of measurements 
were carried out for the sensitivity of bacteria in mice vs. 
addition of the helper compound Amlopidine (Am) and/ 
or the antibiotics Streptomycin (Sm). At t = 0 hours, four 
groups of five mice (20 mice in total) were subject to 1) a 
passive saline injection, 2) injection of 30 μg Am only, 3) 
injection of 60 μg Sm only, and 4) injection of both 30 
μg Am and 60 μg, respectively. Three hours later (at t = 3 
hours), a certain amount of bacteria N (t = 3 hours) was 
next injected into each of the 20 mice. 
Bacteria data were provided for th
ood, liver, and spleen. Here we will restrict ourselves 
to heart blood data for mouse number 1 but other cases 
can be treated similarly. 
For such in-vivo experim
pected to come into play as the mice are not inoculated 
with lethal doses of bacteria. We formulate the model as 
in the following equation: 
 1 3d dP t ε b N  1 4 2 5 1 2ε P N ε P N ε P P N    (3) 
where N is the bacteria population with N (t = 3 hour
mptions so as to extract 
th
 at t = 3 hours corresponding to a 
ba
med to weigh 20 g and the mouse 
m
urs after the injection of 
he
f Am is 10 hours [2] while for Sm it 
is
us to extract in-
fo
cedure is suggested as follows and 
th
ice for 
Sa
 
th
 
co
ing ε1 and b, we can use the Sm injection 
da
·mL·s . Figure 3 (red line). 
e the 
A
 Ta-
bl
 we note that ε3 is orders of magnitude smaller 
th
 demonstrated by using the pa-
ra
s) = 
0.9 × 109 CFU/ml, and P1 and P2 are defined as before. 
The parameter b is the bacteria killing rate due to the 
mouse immune defense system and other effects not at-
tributed to antibiotic or helper compound killing. This is 
a slight simplification of 1) and we use 2) as the injection 
terms similar to the case study. 
We make the following assu
e model parameters: 
Bacteria are injected
cteria concentration equal to N (t = 3 hours) for all 
mice in all organs. 
A mouse is assu
ass density is 1 g/mL. Adding 30 μg Am then corre-
sponds to 1.5 μg/mL Am. Similarly adding 60 μg Sm 
corresponds to 3.0 μg/mL Sm. 
At t = 18 hours (i.e., 15 ho
lper compound and/or antibiotics) they register the 
bacteria population. For 1): 6.5 × 107 CFU/mL, for 2): 
2.0 × 106 CFU/mL, for 3): 8.0 × 105 CFU/mL, and for (d): 
8.8 × 103 CFU/mL. 
The half life t1/2 o
 17 minutes [3]. This means that k1 = log 2/t1/2 = 0.069 
hours–1 and k2 = log 2/t1/2 = 2.4 hours–1. 
We have four data points that allow 
rmation about four of the five quantities: ε1;b; ε3;ε4;ε5. 
Using a guessed value for ε1 the remaining parameters 
can be fitted using the data points. If more independent 
data points were known model parameter verification 
would be possible. 
A calculation pro
e accompanying simulation results for the solution of 
the above set of equations are shown in Figure 3: 
Assuming that the in vivo generation time in m
lmonella is 20 minutes we get ε1 = 5.776 × 10–4 s–1.  
Using the saline injection data, we can calculate b from
e ε1 value by increasing b from 0 until the N value at t = 
18 hours agrees with the measured value Nsat = 6.5 × 107 
CFU/ml. We get b = 6.26 × 10–4s–1. Figure 3 (blue line). 
Knowing ε1 and b, we can use the Am injection data to
mpute ε3 in a similar way until the N value at t = 18 
hours agrees with the measured value NAm = 8.8 × 103 
CFU/ml. We get ε3 = 8.5 × 10–5 μg–1·mL·s–1. Figure 3 
(green line). 
Next, know
ta to compute ε4 until the N value at t = 18 hours agrees 
with the measured value NSm = 8 × 105 CFU/ml (same 
procedure as before). 
We get ε4 = 1.5 μg–1 –1
Knowing ε1, b, ε3 and ε4, we are now able to us
m + Sm injection data to compute ε5 in the same manner: 
We get ε5 = 0.29 μg–1·mL·s–1. Figure 3 (cyan line). 
The results for the coefficients are summarized in
e 2. 
First
an ε4. This shows that the helper compound itself is not 
effective in killing the bacteria in contrast to the antibi-
otics. However, the helper compound and the antibiotics 
together show a synergetic effect which is reflected in the 
significant value of ε5. 
The effect of ε5 can be
meters obtained above for the solution of the system 
but forcing ε5 = 0. This result in a model for the additive 
Copyright © 2012 SciRes.                                                                                 CMB 
C. T. VEJE  ET  AL. 5
 
Figure 3. Results for dynamics using the loop procedure
able 2. Results for the parameters from the analysis of 
meter [Unit] Value 
 
described in the text. Lines are for the model and circles are 
experimental data from Kumar et al. [1]. 
 
T
data from [1]. 
Para
ε1 [s–1] 5. -4 776 × 10
ε3 [μ s–1] 
6.26 × 10-4 
g–1·mL· 8.5 × 10-5 
ε4 [μg–1·mL·s–1] 1.5 
ε5 [μg–1·mL·s–1] 0.29 
b [s–1] 
 
ffect of both Am and Sm without the coupling term—or 
5. Summary and Conclusions 
tion dynamics ap-
odel and ap-
pl
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